Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.990.55%
QQQ
713.000.61%
BTC/USD
77383.031.109%
DIA
523.630.55%
GLD
399.400.77%
TLT
80.870.11%

MiNK Therapeutics Inc

INKTNASDAQ
Trade with Public
Trade with Public
$12.13
0.231.93%
At close: Sep 9, 5:00 PM EST
$11.96
0.060.5%
Pre-Market: 4:00 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

MiNK Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for MiNK Therapeutics (INKT).

Price Target Range — 7 Quarters

Analyst Consensus — 3 Analysts

2Buy
1Hold
Consensus RatingOutperform# Analysts3Avg. Consensus PT$38Upside to Avg. PT+213.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 18, 2026HC Wainwright & Co.Emily BodnarMaintainedBuy$35
Apr 1, 2026HC Wainwright & Co.Emily BodnarMaintainedBuy$35
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the price target from $35 to $35.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains the price target from $35 to $35.
Benzinga Newsdesk

PRO
William Blair Downgrades MiNK Therapeutics to Market Perform

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:INKT) from Outperform to Market Perform.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved